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Chronic kidney disease (CKD) is accompanied by a disturbed redox homeostasis, especially in end-stage patients, which is
associated with pathological complications such as anemia, atherosclerosis, and muscle atrophy. However, limited evidence
exists about redox disturbances before the end stage of CKD. Moreover, the available redox literature has not yet provided clear
associations between circulating and tissue-specific (muscle) oxidative stress levels. The aim of the study was to evaluate
commonly used redox status indices in the blood and in two different types of skeletal muscle (psoas, soleus) in the predialysis
stages of CKD, using an animal model of renal insufficiency, and to investigate whether blood redox status indices could be
reflecting the skeletal muscle redox status. Indices evaluated included reduced glutathione (GSH), oxidized glutathione (GSSG),
glutathione reductase (GR), catalase (CAT), total antioxidant capacity (TAC), protein carbonyls (PC), and thiobarbituric acid
reactive substances (TBARS). Results showed that blood GSH was higher in the uremic group compared to the control
(17 50 ± 1 73 vs. 12 43 ± 1 01, p = 0 033). In both muscle types, PC levels were higher in the uremic group compared to the
control (psoas: 1 086 ± 0 294 vs. 0 596 ± 0 372, soleus: 2 52 ± 0 29 vs. 0 929 ± 0 41, p < 0 05). The soleus had higher levels of
TBARS, PC, GSH, CAT, and GR and lower TAC compared to the psoas in both groups. No significant correlations in redox
status indices between the blood and skeletal muscles were found. However, in the uremic group, significant correlations
between the psoas and soleus muscles in PC, GSSG, and CAT levels emerged, not present in the control. Even in the early stages
of CKD, a disturbance in redox homeostasis was observed, which seemed to be muscle type-specific, while blood levels of redox
indices did not seem to reflect the intramuscular condition. The above results highlight the need for further research in order to
identify the key mechanisms driving the onset and progression of oxidative stress and its detrimental effects on CKD patients.
1. Introduction
Redox homeostasis encompasses the balance between oxi-
dants (or prooxidants) and antioxidants and is maintained
by several complex mechanisms. Redox homeostasis can be
disrupted due to a dysfunction of any of these mechanisms,
resulting in reactive oxygen species (ROS) and/or reactive
nitrogen species (RNS) levels and/or a decreased scavenging
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capacity, a condition which is described as oxidative stress
[1]. ROS, which will form the focus of this work, are highly
reactive to proteins, membrane lipids, carbohydrates, and
nucleic acids, causing irreversible damage which can affect
cell survival and lead to degenerative disorders, disease,
and aging [2].
Chronic kidney disease is accompanied by enhanced oxi-
dative stress, which in turn is associated with higher risk of
developing cardiovascular disease (CVD), leading to high
rates of morbidity and mortality [3, 4]. Moreover, a redox
imbalance in CKD is linked to pathological complications
such as anemia, inflammation, malnutrition and atheroscle-
rosis, fatigue, muscle wasting, and disuse atrophy [5–7].
Although the harmful effects of oxidative stress have been
associated with the progression of CKD, its role during the
different stages of the disease has not yet, been fully clarified.
The majority of the existing data refer to outcomes from the
advanced stages of the disease and mostly to patients under-
going hemodialysis (HD) therapy. In HD patients, four main
factors have been proposed to be responsible for the redox
imbalance: the uremic milieu, the HD treatment per se, the
hemoincompatibility of dialysis system, and the concomitant
drug treatment [8]. However, possible changes in redox
homeostasis during the predialysis stages of CKD have not
been investigated extensively probably due to the fact that
CKD is “silent” at its early stages. Moreover, patients may
progress to renal insufficiency as a secondary outcome of
variable primary conditions, from hypertension, diabetes,
nephrotic syndrome, etc. [9], conditions where monitoring
oxidative stress does not figure as yet as priority of care
due to insufficient evidence for clinical relevance [10].
Oxidative stress in predialysis CKD can be attributed to
the cytotoxic effects of the progressive loss of renal func-
tion as well as insufficient antioxidant defense [11]. Several
mechanisms link CKD and oxidative stress, such as uremic
toxin-induced endothelial nitric oxide synthase (eNOS)
uncoupling [12] and increased nicotinamide adenine dinu-
cleotide phosphate-oxidases (NADPH oxidases (NOX))
activity [13]. Additionally, an emerging antioxidant deficit
has been attributed mainly to dietary restrictions, diuretics
use, protein energy wasting, and/or decreased intestinal
absorption [14, 15].
As renal insufficiency progresses, it is also accompanied
by muscular weakness and wasting, exercise intolerance,
and premature fatigue, characteristics which are collectively
termed as uremic myopathy [16]. Several studies have indi-
cated that CKD is also characterized by modifications of
muscle bioenergetics which also contribute to a reduction
in muscle performance [17–20]. Hemodialysis treatment
and/or uremia per se contributes to an increase in molecular
oxidative damage which in turn can contribute in the deteri-
oration of skeletal muscle functionality. This is because
animal studies have shown that experimentally induced oxi-
dative stress causes myofibrillar protein modification that
promotes degradation free radical oxidation [21–23]. More-
over, the susceptibility of skeletal muscle to ROS may be dif-
ferentiated depending on muscle type (fast vs. slow) [24],
nutrition [25], and lifestyle habits [26]. This and other evi-
dence collectively suggest that skeletal muscle can become
extremely susceptible to degradation due to the combined
effects of uremia and redox disturbances.
The aim of the current study was to evaluate possible
redox disturbances in the predialysis stages of CKD, using
an animal model of renal insufficiency. More specifically,
we evaluated redox status indices not only in the blood
but also in two different types of skeletal muscle, the
fast-twitch/glycolytic psoas and the slow-twitch/oxidative
soleus from the same animal donor. We also examined
whether blood redox status indices could be reflecting the
skeletal muscle redox status.
2. Material and Methods
2.1. Animal Model. The uremic model was based on surgical
protocol modified from Gotloib et al., [22] using sham oper-
ation for the control group. All animal procedures, including
surgery and euthanasia, were approved by the ethics commit-
tee of the University of Thessaly (decision 2-2/10-10-2012
and 914/10-11-2014) and the scientific committee of the
University Hospital of Larisa, Greece (decision 1/4-1-2012).
Animals were under veterinary care, in accordance with the
National and European guidelines for the care and use of
laboratory animals (EU Directive 2010/63/EU for animal
experiments).
New Zealand white rabbits (female, N = 15) were first
acclimatized to the laboratory animal unit of Medical School
(University of Thessaly, Greece) for 48 hours. All animals
were 5-6 months old and weighted approximately 2600 g.
The animals were housed in a controlled environment with
stable conditions of room temperature (RT) (22–24°C) and
lighting (12 : 12 h light-dark cycle). All rabbits were fed with
the same special rabbit chow containing low levels of protein
(78.8 g casein “protein” per kg diet), potassium, calcium,
phosphorus, and sodium (prepared by Research Diets Inc.,
USA; formulation code: D07122101). This was decided
because key biomarkers (e.g., GSH levels) can be affected by
diet [10]. Water was provided ad libitum.
After acclimatization, surgical procedures were per-
formed (sham operation for control animals, control
group, and partial nephrectomy for experimental animals,
uremic group). Animals were anaesthetized by intravenous
administration of a solution mixture of ketamine hydrochlo-
ride 100mg/ml (Imalgene® 1000; Merial, Duluth, Georgia,
USA) and xylazine 20mg/ml (Rompun®; Bayer, Leverkusen,
Germany), 87% and 13%, respectively (proportion 6.69 : 1
approximately). The initial dosage for the induction of
anesthesia was 0.3ml/kg body weight of the above solution
mixture, i.e., Imalgene® (87%) and Rompun® (13%), intrave-
nously (i.v.). The maintenance of anesthesia was achieved by
a dose of propofol (10mg/kg BW). Three hours before the
intervention, each animal had only access to water and not
to food and its weight was measured on a precision scale.
Animal temperature was maintained via a heating pad.
For the uremic group, nine animals (N = 9) underwent
removal of the left kidney after careful ligation of the left
renal artery and vein and partial nephrectomy (3/4) of the
right kidney. For the control group, six age-matched animals
(N = 6) underwent sham operation. Twelve weeks after the
2 Oxidative Medicine and Cellular Longevity
surgery, the animals were weighed and then sacrificed by
injection of sodium pentobarbital solution (50mg/ml) which
was applied in a dosage of 100mg/kg BW followed by bilat-
eral thoracotomy. Immediately after cardiac arrest, sample
collections were done. All sample collection as well as subse-
quent handling and analyses were done in a blind design. It
should be noted that special care was taken not to induce oxi-
dation of glutathione, as mentioned below.
2.2. Blood Sampling and Treatment. Blood samples (5ml)
were collected by a heparinized syringe from rabbits’ heart
and aorta and were placed into ethylene diamine tetra-
acetic acid- (K2EDTA-) containing tubes (Vacutainer Plus
Plastic K2EDTA; Becton Dickinson). For plasma collection,
blood samples were centrifuged immediately at 1370 × g
for 10min at 4°C and the supernatant was carefully col-
lected. The remaining packed erythrocytes were lysed with
1 : 1 (v:v) distilled water, inverted vigorously, and centri-
fuged at 4000 × g for 15min at 4°C. The supernatant red
blood cell (RBC) lysate designated was collected. Finally, in
order to obtain serum, another portion of blood sample
(5ml) was collected and placed into separate tubes contain-
ing clot activator, left for 20min to clot at RT, centrifuged
at 1370 × g, at 4°C for 10min, and the supernatant was col-
lected. All supernatant samples were aliquoted in Eppendorf
tubes, stored at -80°C, and thawed only once before analysis.
2.3. Skeletal Muscle Sampling and Homogenization. Psoas
and soleus muscle samples were harvested from the control
(sham-operated) and uremic groups. These muscles were
selected as two representative muscles, one a typical fast-
twitch muscle (psoas, composed primarily of type IIX
fast-twitch muscle fibers [23, 27]) and the other a typical
slow-twitch muscle (soleus, composed primarily of type I
slow-twitch muscle fibers). Muscle samples were frozen
immediately in liquid nitrogen and stored at -80°C. For anal-
ysis, each tissue sample was thawed, excised, and kept chilled
throughout homogenization. A weighted portion of each
muscle was washed several times with ice-cold normal saline
and was placed into prechilled tubes containing cold homog-
enization buffer (138mM NaCl, 2.7mM KCl, 1mM EDTA,
pH 7.4) and a mix of protease inhibitors (1μΜ aprotinin,
1μg/ml leupeptin, and 1mM PMSF). Initial homogenization
was achieved with an electrical homogenizer (MICCRA D-9)
for 10min with intermediate pauses of 10 s/20 s. Then an
ultrasound homogenizer (UP50H) was used for 1-2min,
with intermediate pauses as before. Homogenates were
filtered through four layers of medical gauze to remove con-
nective tissue debris, incubated for 10min at 4°C, and centri-
fuged at 10,000 × g for 10min at 4°C. The supernatant
homogenate was aliquoted in multiple portions and stored
at -80°C for subsequent analyses.
2.4. Biochemical and Hematological Analyses
2.4.1. Urea, Creatinine. Circulating levels of urea and cre-
atinine were assessed, the two hallmark biomarkers that evi-
dence renal insufficiency [28]; their concentrations in serum
were determined with the colorimetric method using com-
mercially available kits (ab83362, Abcam, United Kingdom,
and ab65340, Abcam, United Kingdom), respectively, with
a 96-well microtiter plate and a programmable microplate
reader (Biochrom, Asys Expert 96, United Kingdom). Urea
and creatinine concentrations in unknown samples were
determined by comparison with the standard curves.
2.4.2. Total Protein. Total protein concentration in plasma
and skeletal muscle (psoas, soleus) homogenates was deter-
mined spectrophotometrically using the bicinchoninic acid
(BCA) protein assay kit (Pierce, Thermo Fisher Scientific,
USA). In plasma, total protein concentration was determined
in order to estimate the final concentration of protein car-
bonyls. In muscle homogenates, total protein concentrations
were determined in order to estimate the final concentrations
of reduced and oxidized glutathione and protein carbonyls as
well as the activities of catalase and glutathione reductase.
2.4.3. Hemoglobin, Hematocrit, and Red Blood Cell (RBC)
Count Analysis. CKD is associated with anemia [29]. Thus,
hemoglobin, hematocrit, and red blood cell count were deter-
mined using a commercially available kit and procedures
(Dutch Diagnostics BV, Zutphen, Netherlands) to examine
if the model promoted the development of anemia.
2.5. Evaluation of Redox Status. All materials for redox
marker assays were purchased from Sigma (St. Louis,
MO, USA). We examined markers for antioxidant capac-
ity, such as TAC, GSH, GR, and CAT, and markers of
protein and lipid oxidation such as protein carbonyls and
TBARS, respectively.
2.5.1. GSH Determination. The tripeptide GSH is the most
abundant nonprotein thiol and one of the main components
of antioxidant capacity [30]. GSH concentration was deter-
mined in RBC lysate and skeletal muscle homogenate sam-
ples according to Rahman et al. [31], using a 96-well
microtiter plate and a programmable microplate reader (Bio-
chrom, Asys Expert 96). Briefly, samples were deproteinized
with 5% trichloroacetic acid (TCA) (1 : 1 v/v) centrifuged at
16,000 × g for 10min, and the supernatant was collected.
The following reagents were added in order (all reagents in
0.1M potassium phosphate buffer, pH 7.5, with 5mM
EDTA) to 96-well flat-bottom plate (CytoOne) in duplicate:
20μl of glutathione standard (0.103 to 26.4μΜ) or the sam-
ple to be assayed, 120μl of freshly prepared (5,5′-dithiobis 2-
nitrobenzoic acid) DTNB (2mg/3ml), glutathione reductase
(10 units), and 60μl of dihydronicotinamide-adenine
dinucleotide phosphate NADPH (2mg/3ml) mix solution
(1v : 1v). The absorbance at 415nm was measured every
30 s, for 3min, at RT. The rate of increase in absorbance
per minute was calculated by linear regression. GSH con-
centration in unknown samples was determined by com-
parison with the standard curve.
2.5.2. GSSG Determination. GSSG concentration was deter-
mined in RBC lysate and skeletal muscle homogenate sam-
ples according to Giustarini et al. [32], modified for using a
96-well microtiter plate and a programmable microplate
reader. Samples were deproteinized with 5% TCA (1 : 1 v/v)
centrifuged at 16,000 × g for 10min, and the supernatant
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was collected. To avoid the rapid oxidation of GSH to
GSSG, through the deproteination procedure, and the con-
sequent overestimation of GSSG, the alkylating reagent N-
ethylmaleimide (NEM) 310mM was added upon collection
of blood sample or the tissue homogenization. This was
extracted before the actual measurement with three vol-
umes of dichloromethane DCM, carefully collecting the
upper volume of the ensuing bilayer (typically 750μl of
DCM for 250μl of deproteinized supernatant), vortexed
5min at 800 rpm at room temperature (RT), and centri-
fuged at 14,000 × g for 30 s at 4°C. To measure GSSG,
the following reagents were added in order (all reagents
in 0.1M potassium phosphate buffer, pH 7.5, with 5mM
EDTA) to 96-well flat-bottom plate (CytoOne) in dupli-
cate: 20μl of glutathione disulfide standard (0.103 to
26.4μΜ) or the sample to be assayed, 120μl of freshly
prepared DTNB (2mg/3ml) and glutathione reductase
(10 units) mix solution (1v : 1v), and 60μl of NADPH
(2mg/3ml). The absorbance at 415nm was measured
every 30 s, for 3min, at RT. The rate of increase in absor-
bance per minute was calculated by linear regression.
GSSG concentration in unknown samples was determined
by comparison with the standard curve.
2.5.3. Determination of GR Activity. Glutathione reductase
(GR) activity is important in the evaluation of tissue redox
state but also has an antiapoptotic role [33]. GR activity
was determined in RBC lysate and skeletal muscle homoge-
nate samples according to Cribb et al. [34], using a 96-well
microtiter plate and a programmable microplate reader.
To measure GR activity, the following reagents were added
in order (all reagents in 0.1M sodium phosphate buffer,
pH 7.5, with 1mM EDTA) to 96-well flat-bottom plate
(CytoOne) in duplicate: 150μl of 0.1mM DTNB, 10μl of
NADPH (10mg/ml; 12mM), and 20μl of reductase stan-
dard (0.015 to 0.50U/ml) or the sample to be assayed.
The reaction was initiated by the addition of 10μl of
GSSG (1mg/ml; 3.25mM). For blank wells, no GSSG
was added. The absorbance at 415nm was measured every
30 s, for 3min, at RT. The rate of increase in absorbance
per minute was calculated by linear regression. GR activity
in unknown samples was determined by comparison with
the standard curve.
2.5.4. TAC Determination. Total antioxidant capacity (TAC)
is a method which is frequently used to assess the antiox-
idant status of biological samples and can evaluate the
antioxidant response against the free radicals produced in
a given condition [35]. TAC was determined in plasma and
skeletal muscle homogenate samples according to Janas-
zewska and Bartosz [36], based on the scavenging of 2,2-
diphenyl-1-picrylhydrazyl (DPPH) free radical. DPPH stock
solution (10mM) was prepared by dissolving 0.02 g DPPH in
5ml of methanol and mix in the stirrer. The working solution
was obtained by diluting the stock solution 100 times with
methanol. In 20μl of plasma or homogenate, 480μl of
10mM sodium potassium phosphate (pH 7.4) and 500μl
of 0.1mM DPPH were added and incubated in the dark
for 30min at RT. The samples were centrifuged for 3min at
20,000 × g and 900μl of the supernatant was transferred into
a clean plastic cuvette. The absorbance was read at 530nm
using a spectrophotometer. TAC values were presented as
mM of DPPH reduced to 2,2-diphenyl-1picrylhydrazine
(DPPH :H).
2.5.5. Determination of CAT Activity. Catalase is a common
enzyme found in nearly all living organisms exposed to
oxygen and catalyzes the decomposition of hydrogen perox-
ide to water and oxygen playing a key role in protecting the
cell from oxidative damage by ROS [37]. CAT activity was
determined in RBC lysate and skeletal muscle homogenate
samples according to Aebi [37]. 20μl of RBC lysate or
homogenate was added to 2975μl of sodium potassium
phosphate buffer 67mM, pH 7.4, and the samples were incu-
bated at 37°C for 10min. 5μl of hydrogen peroxide 30% was
added and the change in absorbance was immediately read at
240 nm for 2min. One unit of catalase is equal to 1μmol of
hydrogen peroxide H2O2 decomposed/minute. Results were
normalized to hemoglobin content in the blood sample and
to total protein content in muscle homogenate samples.
2.5.6. PC Determination. Protein carbonylation is a type of
protein oxidation that can be promoted by ROS. It usually
refers to a process that forms reactive ketones or aldehydes
that can be reacted by 2,4-dinitrophenylhydrazine (DNPH)
to form hydrazones [38]. PC concentration was determined
in plasma and skeletal muscle homogenate samples accord-
ing to Fields and Dixon [39]. In 50μl of plasma or homoge-
nate, 50μl of 20% TCA was added, incubated in the ice
bath for 15min, and centrifuged at 15,000 × g for 5min at
4°C and the supernatant was discarded. Afterwards, 500μl
of 14mM DNPH, in 2.5N hydrochloric acid HCl, for the
sample or 500μl of 2.5N HCl for the blank was added to
the pellet. Both samples were incubated in the dark at RT
for 1 h, with intermittent vortexing every 15min. Samples
were centrifuged at 15,000 × g for 5min at 4°C. The superna-
tant was discarded and 1ml of 10% TCA was added, vor-
texed, and centrifuged at 15,000 × g for 5min at 4°C. The
supernatant was discarded, and 1ml of ethanol-ethyl acetate
(1 : 1 v/v) was added, vortexed, and centrifuged at 15,000 × g
for 5min at 4°C. The washing step was repeated two more
times. Finally, the supernatant was discarded, and 1ml of
5M urea (pH 2.3) was added, vortexed, and incubated at
37°C for 15min. The samples were centrifuged at 15,000 × g
for 3min at 4°C, and the absorbance was read at 375nm. Pro-
tein carbonyl values were obtained by using the molar extinc-
tion coefficient of DNPH (22mM·cm-1).
2.5.7. TBARS Determination. Lipid peroxides are oxidative
degradation products of lipids with malondialdehyde
(MDA) to be considered as the main marker in lipid peroxi-
dation [40]. The TBARS assay is the simplest and most pop-
ular method for quantifying lipid peroxidation in biological
samples [41]. In 100μl of plasma or homogenate, 500μl of
35% TCA and 500μl of 200mM Tris-HCl (pH 7.4) were
added and incubated at RT for 10min. Afterwards, 1ml of
2M sodium sulfate Na2SO4 and 55mM thiobarbituric acid
(TBA) solution was added and incubated at 95°C for
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45min. The samples were cooled on ice for 5min and were
vortexed. 1ml of 70% TCA was added, vortexed, and centri-
fuged at 15,000 × g for 3min at 25°C. The absorbance of the
supernatant was read at 530nm. A baseline absorbance was
taken into account by running a blank along with all samples
during the measurement. The calculation of TBARS concen-
tration was obtained using the molar extinction coefficient of
MDA (15,600mol/l).
2.5.8. Uric Acid Determination. Uric acid is not only a by-
product of purine metabolism, but it can also maintain
protection against oxidative damage acting as an electron
donor and scavenging peroxyl radicals, hydroxyl radicals,
and singlet oxygen [42, 43]. Uric acid concentration in
the serum was measured on a Clinical Chemistry Analyzer
Z 1145 (Zafiropoulos Diagnostica, Athens, Greece) using
commercially available kits (Zafiropoulos Diagnostica).
6μl of serum was added to 600μl of working reagent;
samples were incubated for 1min at 37°C and the absorbance
was read at 340nm.
2.6. Statistical Analysis. Data were analyzed using the com-
mercially available statistical software package SPSS 22.
Results were expressed as mean ± SEM and 95% confi-
dence intervals.
Initially duplicate values were averaged before further
statistical treatment. The Shapiro-Wilk test was performed
to initially test whether the data were normally distributed,
as it was the case.
An independent t-test was conducted to examine
whether there were any differences in blood redox status
indices between the control group and the uremic group.
Similarly, an independent t-test was conducted to examine
whether there were any differences in biochemical and
hematological indices between the control group and the
uremic group.
Two-way MANOVA (two groups × two muscles) was
conducted to examine the effects of uremia and muscle type
on muscle redox status indices. Significant interactions and
main effects were further investigated using LSD post hoc
analysis for multiple group comparisons.
Possible relationships between indices were examined
using Pearson correlation coefficient analysis in pool and
per group (control, uremic) data.
The significance level was set at p ≤ 0 05.
3. Results
Both surgery procedures (3/4 partial nephrectomy and sham
operation) were well tolerated by animals as they presented
with a normal after-surgery recovery. At the end of the
twelve-week period postsurgery, animals’ average body
weight was 3728 ± 336 47 g for control and 2935 ± 288 70 g
for the uremic group (p > 0 05).
3.1. Biochemical and Hematological Analyses. Renal insuffi-
ciency in the uremic group, compared to control, was
reflected in the significantly raised (p < 0 05) blood creatinine
levels (Table 1). However, urea levels were not significantly
different between the groups (p > 0 05). Significant differ-
ences were found in the hematological profile of the uremic
group compared to the control group. More specifically,
hematocrit levels and RBC count were significantly lower in
the uremic group compared to the control (p = 0 005) and
(p = 0 001), respectively. All biochemical and hematological
indices are represented in Table 1.
3.2. Blood Redox Status Analysis. All blood redox status indi-
ces are presented in Table 2. GSH concentration was signifi-
cantly higher in the RBC of the uremic group compared to
the control (t 9 = −2 071, p = 0 033). TBARS concentration
tended to be higher in the plasma of the uremic group com-
pared to the control (p = 0 060). No significant differences
(p > 0 05) were found in the rest of redox status indices eval-
uated in the blood between the two groups. Furthermore, we
found no relationship between TAC levels with hematologi-
cal parameters.
3.3. Muscle Redox Status Analysis. No significant group main
effects were found for antioxidant capacity indices (p > 0 05)
for the two groups. Significant group main effects were found
for PC concentration (F 1,21 = 8 902, p = 0 007) in both
muscle types. The LSD post hoc test revealed that PC con-
centration was significantly higher in the uremic group
compared to the control group. No group main effects
were found for TBARS.
Muscle type appeared to affect the level of some indices
for both the uremic and control groups. Significant muscle
type main effects were found for total protein concentration
(F 1,21 = 23 166, p = 0 001) with protein content of the psoas
being higher than the soleus for both groups. Regarding
Table 1: Biochemical and hematological indices in the control and uremic groups.
Control group (n = 6) 95% confidence interval Uremic group (n = 9) 95% confidence interval p
Lower bound Upper bound Lower bound Upper bound
Total protein (mg/ml) 68 59 ± 2 12 64.44 72.75 67 89 ± 2 28 63.41 72.37 0.825
Creatinine (mg/dl) 1 28 ± 0 15 1.11 1.45 2 45 ± 0 37 1.72 3.19 0.018∗
Urea (mg/dl) 38 ± 4 3 33.43 43.24 60 ± 11 52 37.42 82.58 0.114
Hemoglobin (mg/dl) 11 08 ± 0 92 10.33 11.81 9 80 ± 0 30 8.22 11.77 0.368
Hematocrit (%) 35 24 ± 0 79 34.54 35.93 26 06 ± 1 85 22.43 29.69 0.001∗
RBC (×106/μl) 5 10 ± 0 17 4.95 5.25 3 92 ± 0 29 3.36 4.48 0.005∗
Data are presented as mean ± SEM. The exact statistical significance value p and the 95% confidence intervals are reported.
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antioxidant capacity, GSH concentration (F 1,21 = 6 175,
p = 0 021) was higher in the soleus, TAC levels
(F 1,21 = 18 316, p = 0 001) were higher in the psoas, and
catalase activity (F 1,21 = 20 597, p = 0 001) and GR activity
(F 1,21 = 7 498, p = 0 012) were higher in the soleus in both
the control and uremic groups.
The LSD post hoc test revealed that total protein and
TAC levels were significantly lower in the soleus compared
to the psoas muscle in both the control and uremic groups.
Additionally, the soleus demonstrated higher levels of
TBARS and PC levels as well as higher GSH levels, cata-
lase, and GR activities compared to the psoas muscle in
both groups.
Levels of PC concentration were higher in the soleus
muscle in both groups (F 1,21 = 6 410, p = 0 019) (Figure 1).
TBARS concentration was also higher in the soleus
(F 1,21 = 14 703, p = 0 001) in both the control and uremic
groups, respectively.
Finally, no interactions were found between the exam-
ined muscle types (psoas, soleus) and groups (control, ure-
mic) for all the redox status indices (p > 0 05). All the
results are summarized in Table 3.
3.4. Associations between Blood and Muscle Levels of Redox
Indices. No statistically significant correlation between blood
levels and muscle levels emerged for any of the antioxidant
capacity and the oxidative stress indices examined in this
study. This was the case either in when analysis was per-
formed for the pool of samples or for each group separately
(p > 0 05). Moreover, no correlations between blood levels
and specific muscle type levels were observed (p > 0 05).
Finally, no correlations were found between hematological
indices and antioxidants or oxidative stress indices in the
blood and skeletal muscle (p > 0 05).
Statistically significant correlations emerged from selec-
tive redox status indices, between the two types of skeletal
muscle which however were differentiated by the group.
Thus, in the uremic group, we observed strong and
significant correlations in PC levels (r = 0 913, p = 0 002), in
GSSG levels (r = 0 766, p = 0 027), and in CAT levels
(r = 0 743, p = 0 035) between the soleus and psoas muscle
samples. However, such correlations were not strong or sta-
tistically significant for the control group (Figure 2).
4. Discussion
We examined redox status indices in the blood and in two
different types of skeletal muscle in an animal model mimick-
ing the predialysis stage of CKD. Our main findings were that
PC levels were higher in the uremic group in both muscle
types and that the soleus had higher levels of TBARS, PC,
GSH, CAT, and GR and lower TAC compared to the psoas






















Figure 1: Protein carbonyl concentrations for the psoas (control:
0 596 ± 0 372 nmol/mg protein, 95% CI: lower-upper bound:
0.179-1.370; uremic: 1 086 ± 0 294 nmol/mg protein 95% CI:
lower-upper bound: 0.474-1.699) and the soleus (control: 0 929 ±
0 41 nmol/mg protein, 95% CI: lower-upper bound: 0.063-1.795;
uremic: 2 52 ± 0 29 nmol/mg protein, 95% CI: lower-upper bound:
1.905-3.129) in the control and uremic groups. ∗ depicts
significant differences between the control and uremic groups; †
depicts significant differences between the psoas and soleus
muscles, p < 0 05.
Table 2: Blood redox status indices in the control and uremic groups.
Blood Control group (n = 6) 95% confidence interval Uremic group (n = 9) 95% confidence interval p
Lower bound Upper bound Lower bound Upper bound
Uric acid (mg/dl) 1 39 ± 0 25 0.907 1.886 1 93 ± 0 38 1.18 2.67 0.263
GSH (μmol/g protein) 12 43 ± 1 01 10.448 14.412 17 50 ± 1 73 14.12 20.88 0.033∗
GSSG (μmol/g protein) 0 027 ± 0 006 0.016 0.039 0 048 ± 0 010 0.028 0.067 0.110
Ratio (GSH/GSSG) 481 ± 53 376.357 585.642 425 28 ± 61 19 305.36 545.21 0.511
GR (U/g protein) 176 40 ± 25 127.393 225.423 153 1 ± 15 84 122.04 184.15 0.425
TAC (μmol DPPH/ml) 0 786 ± 0 033 0.719 0.852 0 759 ± 0 041 0.679 0.838 0.611
CAT (U/mg protein) 342 02 ± 17 69 307.35 376.68 303 63 ± 15 63 273.01 334.26 0.131
PC (nmol/mg protein) 0 603 ± 0 09 0.427 0.780 0 620 ± 0 066 0.491 0.748 0.888
TBARS (nmol/ml) 5 12 ± 0 42 4.292 5.948 7 03 ± 0 81 5.44 8.62 0.060
Data are presented as mean ± SEM. The exact statistical significance value p and the 95% confidence intervals are reported. GSH: reduced glutathione; GSSG:
oxidized glutathione; TAC: total antioxidant capacity; CAT: catalase; PC: protein carbonyls; TBARS: thiobarbituric acid reactive substances, ∗ statistical
significance between the control and uremic groups, p < 0 05.






















































































































































































































































































































































































































































































































































































































































































































































































































































































































7Oxidative Medicine and Cellular Longevity
significantly higher in the RBC of the uremic group com-
pared to the control group. Moreover, we found no signifi-
cant correlations in redox status indices between the blood
and skeletal muscle.
The results demonstrated that early during the develop-
ment of CKD there is an alteration in muscle redox homeo-
stasis; importantly, both oxidative damage and antioxidant
capacity seemed to be muscle type-specific. Very impor-
tantly, as it will be discussed below, we observed no associa-
tion between the blood and muscle levels of the biomarkers
examined, which bears significance for their prospective use
in monitoring muscle pathology development.
The animal model was successfully established as it is
reflected by the increases in creatinine and urea in the uremic
group as compared to the control group, in agreement with
observations by others using a similar model (e.g., Taes
et al. [44]). Urea levels in the uremic group were almost
double than those in the control group that difference was
not statistically significant. This could be due to the small
number of animals and animal variability. However, as a
clinical observation, the doubling of urea is indicative of a
considerably compromised renal function [44, 45]. More-
over, the hematological disturbances in the uremic group
(significantly lower hematocrit and RBC compared to con-
trol) indicated the development of anemia, which is similar
to the human condition [29].
Considering the antioxidant capacity, we observed a 40%
higher GSH concentration in uremic blood samples com-
pared to control. GSH is a primary antioxidant molecule
which belongs to the endogenous defense against ROS and
its role is critical for the cellular redox environment [46],
since it is the most abundant nonprotein thiol that counter-
acts oxidative stress [47]. There are conflicting results regard-











































































Figure 2: Correlation of protein carbonyl (PC) concentration (a, b), oxidized glutathione (GSSG) concentration (c, d), and catalase (CAT)
activity (e, f) between the psoas and soleus muscles in the control and uremic groups, respectively. Only in the uremic group correlations
were statistically significant for (b) PC levels (r = 0 913, p = 0 002), (d) GSSG levels (r = 0 766, p = 0 027), and (f) CAT activity (r = 0 743,
p = 0 035).
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appear to depend on the severity of the disease and some-
times not. Thus, in moderately uremic predialysis patients,
Bober et al. found higher levels of GSH compared to age-
matched healthy individuals [48], in agreement to our obser-
vations. However, in other studies, lower GSH levels in the
whole blood of CKD predialysis patients have been observed
compared to controls [49–51] interpreted as a depletion in
the antioxidant reserve. Alhamdani [52] evaluated the
glutathione biosynthetic pathway in advanced uremia and
hemodialysis measuring GSH levels and γ-glutamyl cysteine
synthetase (γ-GCS) and glutathione synthetase (GSH-S)
activities in nondialysis, hemodialysis, and continuous
ambulatory peritoneal dialysis patients. Significant decreases
in GSH levels and γ-GCS activity but not in GSH-S activity
were observed in all groups of patients compared to healthy
individuals. Thus, low activity of γ-GCS, the rate-limiting
enzyme of GSH biosynthesis, may negatively affect de novo
synthesis of GSH in those patients with low levels of GSH.
The observed increased levels of GSH concentration in
uremic blood samples in our study could be attributed to
an upregulation of its synthesis in response to a greater
demand, especially, given the almost doubling of blood GSSG
in the uremic group (levels being 1.77-fold of those of the
control group). This observation, despite not reaching statis-
tical significance, indicates a tendency for increased levels of
hydrogen peroxide or lipid peroxides, similar to human stud-
ies [50]. Nonetheless, CAT also reduces hydrogen peroxide
to water, but there was no statistical difference in the activity
of the specific antioxidant enzyme between the two groups in
our study (still, CAT activity tended to be lower in erythro-
cytes of the uremic group). CAT is located in peroxisomes
while GSH and GPx are found mainly in the cytosol [53].
This subcellular compartmentalization is undoubtedly
important for hydrogen peroxide detoxification. Based on
the above, it appeared that hydrogen peroxide scavenging
in circulation was undertaken to a greater degree by the
glutathione redox cycling mechanism than CAT in our
CKD model.
In patient studies, while general clinical guidelines are
followed, dietary approaches can greatly influence GSH
levels, contributing to literature’s conflicting reports. GSH
concentration is decreased by fasting, low-protein diets, or
diets limiting in sulfur amino acids such as cysteine [54].
However, administration of α-lipoic acid, a naturally occur-
ring thiol compound, increases GSH levels in several cell
types and tissues [54–56] and also restores intracellular
GSH in several pathological conditions [54]. Moreover,
selenium (Se) as an integral part of the enzyme GPx plays
a key role in GSH levels [57]. In our study, both control
and uremic animals followed the same diet, carefully
designed not to tax the remaining kidney function, simi-
larly to diet guidelines followed by patients, while providing
balanced nutrients and minerals, to minimize any diet-
induced effect on GSH levels.
Muscle analysis per group and per muscle type indicated
redox disturbances in the skeletal muscle of the uremic
group. The significant increase in PC levels by approximately
1.82-fold for the psoas and 2.71-fold for the soleus in uremic
compared to control psoas and soleus, respectively, points to
increased levels of sarcomeric protein carbonylation. It is well
established that oxidized proteins undergo diverse structure
and functional changes including change in their hydropho-
bicity which makes them more susceptible to proteolysis
[58]. Carbonylation, which is an irreversible and irreparable
protein modification, tags proteins to be led through proteol-
ysis or to form high-molecular weight aggregates through
direct oxidation of side chains of lysine, arginine, proline,
and threonine residues, among other amino acids. Such car-
bonylated aggregates can become cytotoxic and have been
associated with a large number of age-related disorders [59].
Moreover, our findings are in agreement with those
reported by Lim et al. [60] in the skeletal muscle of HD
patients. Our results of increased PC levels in the skeletal
muscle of the animal model, and the available patient evi-
dence by Lim et al., fit with the projection of the development
of muscle atrophy, which is a well-established component of
uremic myopathy in end-stage hemodialysis patients [61].
Such interpretation is also corroborated by the recent finding
of moderate atrophy in the psoas muscle fibers of chronically
uremic animals [62]. Moreover, Lim et al. also found
increased TBARS levels, for which, in agreement to the over-
all disease profile, we reported a tendency for increased levels
in the muscle. We cannot exclude the formation of protein
aggregates, but considering other evidence on progressive
atrophy and the young age of the animals studied, we con-
sider that increased PC levels are a plausible indication of
atrophy mechanisms under way in predialysis stages of renal
insufficiency. Taking into account the role of carbonyl stress
in vascular damage [63] and the generally impaired function-
ality of the muscle in CKD [61, 62], early measures protecting
muscle protein and vasculature from oxidation could prove
of great importance for patients before progressing into the
end stage where HD aggravates the redox imbalance [11]
and further negative effects on muscle status accumulate.
The observed tendency for an increase in blood TBARS
levels of the uremic group compared to the control group
possibly revealed a predisposition towards lipid peroxidation
[64], a pathogenetic factor in atherosclerosis [65]. Further-
more, lipid peroxidation negatively affects erythrocyte mem-
brane integrity, playing a major role to their half-life
shortening and thus to the development of anemia [56]. This
agrees with our observation of lower RBC and Hct in our pre-
dialysis model. Papavasiliou et al. [66] found statistically sig-
nificant increased TBARS levels in the plasma of predialysis
patients with stages 3-5 CKD compared to healthy individ-
uals. In the same study, patients on stages 1-2 CKD exhibited
a tendency for higher TBARS levels compared to healthy
individuals. In addition, stages 1-2 CKD patients exhibited
significantly lower MDA levels compared to the stages 3-5
CKD patients [66]. Regarding HD patients, the large majority
of studies reported increased TBARS levels in the plasma
compared to healthy individuals [48, 63, 67–70], reflecting
extensive lipid peroxidation, while erythropoietin treatment
can help mitigate redox disturbances and inflammation,
especially in the long term [70].
Taking all the above into consideration together with our
findings, it could be concluded that blood lipid peroxidation
in CKD emerges from the early stages of renal insufficiency.
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Skeletal muscle wasting is a characteristic of several
chronic diseases [71] including kidney disease. In previous
work, some of us have demonstrated a fiber-type specificity
of atrophy in HD patients [61, 72]. Here, we examined the
redox status of the slow-twitch soleus (expressing mainly
myosin heavy chain type I) and the fast-twitch psoas
(expressing mainly the fast myosin heavy chain IIX) [23,
27]. Overall, the soleus muscle presented with higher levels
of TBARS and PC levels but also with higher GSH levels
and catalase and GR activities compared to the psoas muscle
in both groups. Thus, while due to its mitochondrial content,
the soleus may be expected to experience a higher oxidative
stress load at the same time it appeared better equipped to
withstand it, in agreement with the limited literature existing
in patients [4].
One of the suggested mechanisms to explain muscle
catabolism involves the tumor necrosis factor-α (TNF-α)
[73, 74], via the regulation of hormones and catabolic cyto-
kines [75–77] and can also promote muscle loss by stimulat-
ing the ubiquitin gene expression [78] and activating the
nuclear factor NF-κB [79]. In HD patients, Li et al. [80]
observed that TNF-α can directly trigger protein loss and
decrease in myosin heavy chain fast (MHCf) levels in the
skeletal muscle. It is also known that TNF-α/NF-κB signaling
pathway is widely affected from endogenous ROS. TNF-α
widely excites mitochondria ROS production, promoting
TNF-α/NF-κB activation [81, 82], a process which seems to
be tissue-specific [80]. In line with these reports, human
studies [4] indicate greater atrophy in fast-twitch muscles,
perhaps via mitochondrial dysfunction in the uremic envi-
ronment. Taking into consideration that fast muscle is the
type mostly affected in patients [61], perhaps the redox dis-
turbances in the psoas muscle eventually contributes to the
literature observations of atrophy. On the other hand,
despite the expected increased levels of mitochondrial func-
tion, the presence of higher concentrations of GSH, CAT,
and GR in our study indicated that healthy soleus may have
a higher antioxidant capacity than healthy psoas. In response
to an augmented oxidative load due to renal insufficiency,
uremic soleus appears to have further upregulated its
defenses in the predialysis CKD stage, resisting the detrimen-
tal effects of ROS.
The present study evaluated the possible relationships
between redox status indices in the blood and skeletal muscle
under chronic renal insufficiency. Notably, we observed no
correlation between the redox indices evaluated in the blood
and their levels in the two different types of skeletal muscle
(psoas, soleus). Correlation analysis was further expanded
to explore the differences obtained in the redox markers at
the blood and muscle levels in relation to parameters related
to the development of anemia. However, we observed no cor-
relation between these indices.
Although the accessibility to all tissues is feasible in ani-
mal models providing the opportunity to evaluate redox sta-
tus in the tissue of interest, in humans, several difficulties and
ethical limitations in such invasive processes exist, especially
in patients. Thus, in the majority of human studies, redox
status indices have been evaluated in the blood and results
are extrapolated in tissues. However, due to limited studies
[83, 84], it remains uncertain if and in which cases evaluating
redox status indices in the blood adequately reflects the redox
status in tissues. Rodriguez et al. [83] found that protein
carbonyl concentrations were moderately (r = 0 51) corre-
lated between the blood and skeletal muscle (vastus lateralis)
in patients with chronic obstructive pulmonary disease. Ves-
koukis et al. [84] reported that four redox status indices (PC,
GSH, GSSG, and catalase) in the blood adequately reflected
the oxidative stress changes that happened in healthy skeletal
muscle (rat gastrocnemius) after exercise and/or xanthine
oxidase inhibition. This discrepancy could be explained by
the differences in methodology adopted such as the type of
animal model, muscle used (e.g., in Veskoukis et al. gastroc-
nemius, which has a different myosin composition than rab-
bit psoas), lab protocols, and the renal dysfunction per se
having possibly an overarching systemic effect that could
mask muscle’s contribution to blood levels of redox indices.
If a disease state is implicated then not only the primarily
suffering organic system could be contributing to a redox
imbalance (as e.g., the kidney [85]) but also secondarily
affected systems (e.g., muscle), as well as systemic inflamma-
tion [60, 86] and vascular stress [87] could be implicated.
Measuring redox status in the blood in such a complex state
may not thus allow clear conclusions with regard to tissue
levels because high levels of generalized oxidative stress or
increased blood antioxidant capacity could be masking the
contribution of oxidative damage originating in the skeletal
muscle. We cannot exclude the possibility that if uremic or
control animals were exercised blood ROS levels might have
reflected skeletal muscle levels. Based however on our data, in
a small number of animals, with tissue samples on the resting
state, we cannot presently recommend that any blood
marker, among those studied, could reliably reflect intramus-
cular redox status.
The findings of this study should be considered in the
light of some limitations. We observed statistically significant
correlations in the levels of critical redox indices between the
soleus and the psoas in the uremic group and not in the con-
trol, which could partly reflect the disease-induced modifica-
tion of muscle properties without excluding an effect of small
sample size. A bigger number of animals could better clarify
the tendencies for some indices examined, perhaps also
including a nonoperated control group. However, due to
the high cost of the model and ethical considerations, this
was not possible in the present work. While we implemented
an extensive panel of redox homeostasis, based on the estab-
lished laboratory expertise, future work could extend this
assessment to additional redox indices and enzymes (e.g.,
those upstream of catalase such as superoxide dismutase
(SOD)) or also consider the emerging ratio between SOD
and CAT [88], the role of peroxiredoxin proteins [89]. More-
over, future work should examine the interplay between
molecular mechanisms of atrophy and renal insufficiency as
well as the association between a set of inflammatory bio-
markers and the progression of CKD. Finally, it could be
of interest to obtain data from a group of uremic rabbits
also treated with antioxidant compound to evaluate the
responsiveness of redox balance in the blood and in the
muscle tissues.
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5. Conclusion
In conclusion, the results of this work demonstrate that even
in the predialysis stages of CKD there is an emergence of oxi-
dative stress in the blood and a possibly adaptive response by
the upregulation of the blood antioxidant defense. Moreover,
carbonyl formation in both fast and slow skeletal muscle
types, an indication of protein oxidation that can lead to pro-
tein degradation and proteolysis, emerges as a plausible early
stimulus towards muscle atrophy observed later in advanced
CKD. Last but not the least, it was found that blood levels of
the redox status indices studied here did not reflect muscle
concentrations. More work is needed in the direction of suc-
ceeding in less invasive monitoring of early muscle-related
redox imbalances taking into consideration specific disease
effects, age, and available techniques.
Our results showed redox disturbances both in the blood
and muscle in an early stage of renal insufficiency, highlight-
ing the need for further research in redox challenges imposed
by chronic renal insufficiency on the skeletal muscle with a
view of preserving muscle status before progression to the
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